Laquinimod for multiple sclerosis
| Author : Pierre Allain
||Date : 2012-4-21
Laquinimod is a derivative of linomide, also called roquinimex, which was tested for the treatment of multiple sclerosis before being dropped out for adverse effects.
The Allegro study published in the NEJM March 15, 2012, shows that laquinimod, used in the treatment of multiple sclerosis, reduced the frequency of relapses and the progression of the disease in a modest way (modest is the term used by the authors of the article themselves). Among the adverse effects of laquinimod are elevated hepatic enzymes and low back pain. The mechanism of action of laquinimod is not clearly specified.
Chemical structure of laquinimod